News

Nasoni Takes the Lead in Transforming Care for Alzheimer’s and Dementia Patients with $2.4M Federal Grant

Hampton Roads stands at the forefront of innovation by announcing a $2.4 million federal grant to enhance care for Alzheimer’s and dementia patients. This funding, spearheaded by Congresswoman Jen Kiggans, not only highlights the region’s commitment to healthcare but also emphasizes the role of local startups like Nasoni, which are driving the future of patient care.

Nasoni, a forward-thinking Hampton Roads startup known for its innovative faucet designs, is expanding its reach into healthcare with solutions that improve the quality of life for patients facing cognitive challenges. As part of the broader effort supported by the federal grant, Nasoni will play a crucial role in developing practical, user-friendly technologies to assist patients and caregivers alike.

Their patented faucets, designed with ease of use in mind, are particularly valuable for individuals with Alzheimer’s and dementia. With simple features that allow for better access to clean water, Nasoni’s faucets reduce daily stress and improve hydration—an often overlooked but critical aspect of care for aging populations.

Founder Steve Waddell is optimistic about Nasoni’s impact. “Our goal has always been to make life easier through innovative design,” Waddell says. With this grant, we can extend that mission to vulnerable populations in Hampton Roads, providing practical solutions that ease the burdens of care.”

Kiggans, a former geriatric nurse practitioner, recognizes the importance of such local innovations. “Companies like Nasoni are key to revolutionizing the way we support Alzheimer’s and dementia patients. Their commitment to improving everyday tasks like access to clean water aligns with our goal of enhancing patient care in meaningful ways,” she shared during the announcement.

In addition to Nasoni’s contributions, the grant will fund various community-based programs, caregiver training, and healthcare initiatives designed to enhance early detection and personalized care strategies. By combining Nasoni’s innovative products with these expanded services, Hampton Roads is set to become a model for Alzheimer’s and dementia care.

The collaboration between local businesses and healthcare providers underscores the region’s thriving ecosystem of startups and technology. As Nasoni continues to expand its influence, its work will serve as a shining example of how ingenuity can positively impact patient care on a large scale.

This grant not only advances the fight against Alzheimer’s and dementia but also highlights the role of Hampton Roads startups in solving critical healthcare challenges. With Nasoni’s help, the future of care in the region looks brighter than ever.

 

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like